journal article·2026-05Open access

Dual Ferroptosis‐Inhibitory and Antifungal Therapy for Fungal Keratitis Using a Defect‐Adhesive Thermoresponsive Hydrogel

Ling Wang, Haiping Zhong, Hui Zhang, Rongjie Wei, Maoyu Cai, Liangpin Li, Xueyan Zhou, Xia Hua, Shutao Guo, Xiaoyong Yuan

Advanced Healthcare Materials· Volume 15· Issue 17

Abstract

ABSTRACT Fungal keratitis is a major cause of corneal blindness and remains difficult to treat due to poor drug retention, frequent dosing, and inadequate modulation of pathogenic mechanisms. Current therapies largely focus on antifungal efficacy while neglecting inflammation‐, fibrosis‐, and cell death–related pathways. Here, ferroptosis is identified as a critical pathogenic target, and a synergistic therapeutic strategy is developed using a thermosensitive in situ‐forming hydrogel composed of poloxamer and hyaluronic acid, enabling the co‐delivery of a ferroptosis inhibitor (ferrostatin‐1, Fer‐1) and the antifungal agent (voriconazole, VOR), termed PX/HA/Fer‐1/VOR hydrogel. Upon administration, the hydrogel exhibits lens‐like adhesion to corneal defects, forming a localized drug reservoir that significantly enhances corneal retention and prolongs drug residence time by at least 90 min. In vitro studies demonstrate enhanced antifungal activity, while in vivo fungal keratitis models show superior therapeutic efficacy compared with conventional voriconazole eye drops administered six times daily. Notably, a single daily application effectively suppresses inflammation, reduces corneal fibrosis and scarring, and promotes recovery of visual function. Mechanistically, the composite hydrogel exerts synergistic effects through zinc ion chelation–mediated antifungal activity, inhibition of ferroptosis, and attenuation of fibrosis. This multifunctional hydrogel platform offers a promising therapeutic strategy for fungal keratitis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal Surgery and Treatments · Nanoplatforms for cancer theranostics · Ocular Infections and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Key Laboratory of Ophthalmology and Visual Science Tianjin Eye Institute Tianjin Eye Hospital Tianjin China

Department of Ophthalmology Division of Life Sciences and Medicine the First Affiliated Hospital of University of Science and Technology of China, USTC Hefei China

Key Laboratory of Functional Polymer Materials of the Ministry of Education State Key Laboratory of Medicinal Chemical Biology and Institute of Polymer Chemistry College of Chemistry Nankai University Tianjin China

School of Biomedical Engineering Guangzhou Medical University Guangzhou China

Clinical College of Ophthalmology Tianjin Medical University Tianjin China

College of Medicine Nankai University Tianjin China

Aier Eye Institute Changsha China

Tianjin Aier Eye Hospital Tianjin China

Funding

National Natural Science Foundation of China · Tianjin Municipal Science and Technology Program · Natural Science Foundation of Tianjin Municipality

References (50)

Show source-provided references
1. 10.1016/j.jtos.2021.12.00110.1016/j.jtos.2021.12.001 ↗
2. 10.1016/S1473‐3099(20)30448‐510.1016/S1473‐3099(20)30448‐5 ↗
3. 10.1007/978-3-030-21735-8_210.1007/978-3-030-21735-8_2 ↗
4. 10.1016/j.survophthal.2021.08.00210.1016/j.survophthal.2021.08.002 ↗
5. 10.3389/fcimb.2023.109418210.3389/fcimb.2023.1094182 ↗
6. 10.1007/s11046‐022‐00666‐110.1007/s11046‐022‐00666‐1 ↗
7. 10.1016/j.exer.2020.10837210.1016/j.exer.2020.108372 ↗
8. 10.1128/AAC.41.11.249210.1128/AAC.41.11.2492 ↗
9. 10.1086/36793310.1086/367933 ↗
10. Clinical Utility of Voriconazole Eye Drops in Ophthalmic Fungal Keratitis
11. 10.3390/ijms2403234310.3390/ijms24032343 ↗
12. 10.1016/j.ophtha.2017.05.01210.1016/j.ophtha.2017.05.012 ↗
13. 10.1021/acsnano.6b0060110.1021/acsnano.6b00601 ↗
14. 10.1038/s41467‐024‐53410‐210.1038/s41467‐024‐53410‐2 ↗
15. 10.1021/acsnano.2c0744410.1021/acsnano.2c07444 ↗
16. 10.1016/j.biomaterials.2024.12257010.1016/j.biomaterials.2024.122570 ↗
17. 10.1002/advs.20241117210.1002/advs.202411172 ↗
18. 10.1016/j.redox.2021.10197110.1016/j.redox.2021.101971 ↗
19. 10.1016/j.canlet.2017.12.02510.1016/j.canlet.2017.12.025 ↗
20. 10.1167/iovs.10‐565910.1167/iovs.10‐5659 ↗
21. Ocular Surface Temperature
22. 10.1016/j.xphs.2018.01.01910.1016/j.xphs.2018.01.019 ↗
23. 10.1039/D4SM00476K10.1039/D4SM00476K ↗
24. 10.7150/thno.10326610.7150/thno.103266 ↗
25. 10.1016/j.ijpharm.2025.12539410.1016/j.ijpharm.2025.125394 ↗
26. 10.3390/pharmaceutics1003011010.3390/pharmaceutics10030110 ↗
27. 10.1002/jcp.104159030510.1002/jcp.1041590305 ↗
28. 10.1136/bjo.2003.02757310.1136/bjo.2003.027573 ↗
29. 10.1016/j.micpath.2019.10380210.1016/j.micpath.2019.103802 ↗
30. 10.3390/molecules2518403510.3390/molecules25184035 ↗
31. 10.3390/membranes1304043610.3390/membranes13040436 ↗
32. 10.1002/cbic.20170010510.1002/cbic.201700105 ↗
33. 10.1073/pnas.151119711210.1073/pnas.1511197112 ↗
34. 10.1039/C5SC03655K10.1039/C5SC03655K ↗
35. 10.1111/1348‐0421.1259610.1111/1348‐0421.12596 ↗
36. 10.1155/2016/653805110.1155/2016/6538051 ↗
37. 10.3390/pharmaceutics1003015910.3390/pharmaceutics10030159 ↗
38. 10.1016/j.preteyeres.2020.10084210.1016/j.preteyeres.2020.100842 ↗
39. 10.1038/s41423‐021‐00667‐y10.1038/s41423‐021‐00667‐y ↗
40. 10.3390/gels912093310.3390/gels9120933 ↗
41. 10.1002/btm2.1027610.1002/btm2.10276 ↗
42. 10.1016/j.ophtha.2021.09.01910.1016/j.ophtha.2021.09.019 ↗
43. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
44. 10.1016/j.cub.2023.02.06010.1016/j.cub.2023.02.060 ↗
45. 10.1038/s41580‐023‐00648‐110.1038/s41580‐023‐00648‐1 ↗
46. 10.1016/j.freeradbiomed.2023.10.40910.1016/j.freeradbiomed.2023.10.409 ↗
47. 10.1016/j.redox.2024.10335410.1016/j.redox.2024.103354 ↗
48. 10.1007/s11010‐022‐04644‐510.1007/s11010‐022‐04644‐5 ↗
49. 10.1167/iovs.65.2.2910.1167/iovs.65.2.29 ↗
50. 10.1186/s12951‐024‐02784‐y10.1186/s12951‐024‐02784‐y ↗